Trevena, Inc. (NASDAQ:TRVN – Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.24 and traded as low as $1.30. Trevena ...

3月19日，港股 创新药 企业云顶新耀（1952.HK）宣布，正式启动位于浙江嘉善工厂的伊曲莫德（VELSIPITY®）生产建设项目。这一举措将有力推动伊曲莫德的本地化生产进程，同时为公司的mRNA技术产业化战略奠定坚实基础。

Researchers investigated the potential association between plasma apolipoprotein M (APOM) levels and the risk of adverse ...

Also emerging are oral therapies including Bristol-Myers Squibb's S1P therapy Zeposia (ozanimod) – with Arena Pharma's etrasimod following closely after in phase 3 – as well as newer JAK ...

Orally-active S1P agonist Zeposia (ozanimod) has been submitted to the FDA as a treatment for adults with moderately to severely active ulcerative colitis (UC), with a decision from the US ...

Metabolic syndrome is a disorder of energy use and storage. This syndrome is characterized by central obesity, dyslipidaemia, raised blood pressure and high blood sugar levels. Patients with ...